Dr. Venook on Looking Ahead at Treatment for CRC

Video

In Partnership With:

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses future steps for treatment of patients with colorectal cancer.

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses future steps for treatment of patients with colorectal cancer (CRC).

Neither targeted therapies or immunotherapy should be the one-size-fits-all approach to treating patients with CRC, Venook explains. While it would be ideal to eliminate chemotherapy from the treatment landscape, there is a misconception that targeted therapies are not associated with any adverse events.

Additionally, Venook predicts that practitioners will eventually stage patients based on their biology versus conventional pathology. There are potentially 4 or 5 genetic subgroups of CRC that require individual treatment approaches, which will likely improve outcomes for patients going forward, he says.

Related Videos
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD